Abbott (NYSE: ABT) CFO receives major option and stock grants

Rhea-AI Filing Summary

ABBOTT LABORATORIES executive Philip P. Boudreau, EVP and CFO, reported equity awards. On February 24, 2026, he acquired an employee stock option for 115,413 shares with no exercise price shown here, granted under the Abbott Laboratories 2017 Incentive Stock Program and scheduled to become exercisable in three equal annual installments beginning February 24, 2027.

On the same date, he also received a performance-based restricted stock award of 27,997 common shares without par value, with a three‑year term and no more than one‑third vesting in any year, contingent on Abbott reaching a minimum return on equity target and allowing share withholding for taxes. Following these awards, he directly owned 78,613 common shares and indirectly held 366 shares through an Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Boudreau Philip P

Role EVP AND CFO

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	115,413	$0.00	--
Grant/Award	Common shares without par value	27,997	$0.00	--
holding	Common shares without par value	--	--	--

Holdings After Transaction: Option (right to buy) — 115,413 shares (Direct); Common shares without par value — 78,613 shares (Direct); Common shares without par value — 366 shares (Indirect, Profit Sharing Trust)

Footnotes (1)

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,471 on February 24, 2027, 38,471 on February 24, 2028, and 38,471 on February 24, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boudreau Philip P

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	02/24/2026		A		27,997(1)	A	$0	78,613	D
Common shares without par value								366(2)	I	Profit Sharing Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)(3)	$114.6	02/24/2026		A		115,413		02/24/2027	02/23/2036	Common Shares	115,413	$0	115,413	D

Explanation of Responses:

1. These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.

2. Balance in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,471 on February 24, 2027, 38,471 on February 24, 2028, and 38,471 on February 24, 2029.

	/s/ Philip P. Boudreau, by Jessica H. Paik, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ABBOTT LABORATORIES (ABT) report for Philip P. Boudreau?

ABBOTT LABORATORIES reported that EVP and CFO Philip P. Boudreau received an employee stock option for 115,413 shares and a performance-based restricted stock award of 27,997 common shares on February 24, 2026, both under the Abbott Laboratories 2017 Incentive Stock Program.

What are the key terms of the ABBOTT LABORATORIES (ABT) stock option granted to Philip P. Boudreau?

The employee stock option for 115,413 shares becomes exercisable in three equal annual increments of 38,471 shares on February 24, 2027, 2028, and 2029. It was granted under the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b‑3.

How does the ABBOTT LABORATORIES (ABT) performance-based restricted stock award vest for Philip P. Boudreau?

The performance-based restricted stock award of 27,997 shares has a three‑year term, with no more than one‑third of the award vesting in any year. Vesting depends on Abbott reaching a minimum return on equity target, and the award permits shares to be withheld for taxes.

What is Philip P. Boudreaus total ABBOTT LABORATORIES (ABT) share ownership after these awards?

After the reported awards, Philip P. Boudreau directly owned 78,613 ABBOTT LABORATORIES common shares and indirectly held 366 shares through the Abbott Laboratories Stock Retirement Trust as of February 24, 2026, reflecting his combined direct and indirect equity stake.

How are indirect ABBOTT LABORATORIES (ABT) shares held for Philip P. Boudreau?

Philip P. Boudreaus indirect ABBOTT LABORATORIES holdings consist of 366 common shares in the Abbott Laboratories Stock Retirement Trust as of February 24, 2026. These shares are reported as indirect ownership associated with a profit sharing or retirement trust structure.